Drug Patents Expiring in 2033

1. Drug name - ABILIFY MAINTENA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11154553 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function Sep, 2033

(10 years from now)

US10980803 OTSUKA PHARM CO LTD Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function Sep, 2033

(10 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; treatment of schizophrenia; maintenance monotherapy treatment of bipolar i disorder; Treatment of schizophrenia; treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
300MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
300MG FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
400MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
400MG FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

2. Drug name - ABILIFY MYCITE KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9268909 OTSUKA Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device Oct, 2033

(11 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Method of using a logic circuit to stabilize battery voltage supplied to a sensor embedded with a tablet and that communicates information via a signal through the body of a patient to a receiver

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription

3. Drug name - ACZONE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9161926 ALMIRALL Topical dapsone and dapsone/adaplene compositions and methods for use thereof Nov, 2033

(11 years from now)

US9517219 ALMIRALL Topical dapsone and dapsone/adapalene compositions and methods for use thereof Nov, 2033

(11 years from now)

Drugs and Companies using DAPSONE ingredient

Treatment: Topical treatment of acne vulgaris

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
7.5% GEL;TOPICAL Prescription

4. Drug name - AKLIEF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9498465 GALDERMA LABS LP Topical compositions in the form of a gel containing a particular solubilized retinoid May, 2033

(10 years from now)

US9084778 GALDERMA LABS LP Topical compositions containing a retinoid of the oil-in-water emulsion type May, 2033

(10 years from now)

Drugs and Companies using TRIFAROTENE ingredient

Treatment: Topical treatment of acne vulgaris; Treatment of acne vulgaris

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.005% CREAM;TOPICAL Prescription

5. Drug name - ALKINDI SPRINKLE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9675559 ETON Treatment of adrenal insufficiency Jan, 2033

(10 years from now)

Drugs and Companies using HYDROCORTISONE ingredient

Treatment: Treatment of adrenal insufficiency

Dosage: GRANULE;ORAL

More Information on Dosage
Strength Dosage Availability
0.5MG GRANULE;ORAL Prescription
1MG GRANULE;ORAL Prescription
2MG GRANULE;ORAL Prescription
5MG GRANULE;ORAL Prescription

6. Drug name - ANTARA (MICRONIZED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9314447 LUPIN Reduced dose pharmaceutical compositions of fenofibrate May, 2033

(10 years from now)

Drugs and Companies using FENOFIBRATE ingredient

Treatment: Treating primary hypercholesterolemia and mixed dyslipidemia; treating severe hypertriglyceridemia

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG CAPSULE;ORAL Prescription
43MG CAPSULE;ORAL Prescription
87MG CAPSULE;ORAL Discontinued
90MG CAPSULE;ORAL Prescription
130MG CAPSULE;ORAL Prescription

7. Drug name - ARISTADA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9193685 ALKERMES INC Pharmaceutical compositions having improved storage stability Oct, 2033

(11 years from now)

US11097006 ALKERMES INC Pharmaceutical compositions having improved storage stability Oct, 2033

(11 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
441MG/1.6ML (275.63MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
662MG/2.4ML (275.83MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
882MG/3.2ML (275.63MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
1064MG/3.9ML (272.82MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

8. Drug name - ARYMO ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549899 ZYLA Abuse deterrent pharmaceutical compositions for controlled release Jul, 2033

(10 years from now)

US9044402 ZYLA Abuse-deterrent pharmaceutical compositions for controlled release Jul, 2033

(10 years from now)

Drugs and Companies using MORPHINE SULFATE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET, EXTENDED RELEASE;ORAL Discontinued
30MG TABLET, EXTENDED RELEASE;ORAL Discontinued
60MG TABLET, EXTENDED RELEASE;ORAL Discontinued

9. Drug name - AUSTEDO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9550780 TEVA BRANDED PHARM Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Sep, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9296739 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Sep, 2033

(10 years from now)

US9233959 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Sep, 2033

(10 years from now)

US9814708 TEVA BRANDED PHARM Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Sep, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
6MG TABLET;ORAL Prescription
9MG TABLET;ORAL Prescription
12MG TABLET;ORAL Prescription

10. Drug name - BAXDELA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582 MELINTA Alkylated cyclodextrin compositions and processes for preparing and using the same Feb, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 300MG BASE/VIAL POWDER;INTRAVENOUS Prescription

11. Drug name - BELSOMRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10098892 MERCK SHARP DOHME Solid dosage formulations of an orexin receptor antagonist May, 2033

(10 years from now)

Drugs and Companies using SUVOREXANT ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription

12. Drug name - BENDEKA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000021 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration Mar, 2033

(10 years from now)

US9597398 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9144568 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US10052385 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9597399 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9034908 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9597397 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9572887 EAGLE PHARMS Formulations of bendamustine Mar, 2033

(10 years from now)

US9579384 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration Mar, 2033

(10 years from now)

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; for the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients with chronic lymphocytic leukemia; for the treatment of patients with indolent b-cell non-hodgkin lymphoma

Dosage: SOLUTION;IV (INFUSION)

More Information on Dosage
Strength Dosage Availability
100MG/4ML (25MG/ML) SOLUTION;IV (INFUSION) Prescription

13. Drug name - BIKTARVY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9732092 GILEAD SCIENCES INC Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections
Dec, 2033

(11 years from now)

US9216996 GILEAD SCIENCES INC Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
Dec, 2033

(11 years from now)

CN104995198A GILEAD SCIENCES INC Polycyclic - Carbamoyl-Pyridone Compounds And Pharmaceutical Use
Dec, 2033

(11 years from now)

CN107674086B GILEAD SCIENCES INC Polycyclic-Carbamoyl Pyridone Compounds And Pharmaceutical Use Thereof
Dec, 2033

(11 years from now)

CN104995198B GILEAD SCIENCES INC Polycyclic Carbamoyl Pyridone Compounds And Pharmaceutical Use Thereof
Dec, 2033

(11 years from now)

CN107674086A GILEAD SCIENCES INC Polycyclic Carbamoyl Pyridone Compounds And Pharmaceutical Use Thereof
Dec, 2033

(11 years from now)

IN201505535P1 GILEAD SCIENCES INC Polycyclic Carbamoylpyridone Compounds And Their Pharmaceutical Use
Dec, 2033

(11 years from now)

IN371130B GILEAD SCIENCES INC Polycyclic Carbamoylpyridone Compounds And Their Pharmaceutical Use
Dec, 2033

(11 years from now)

IN201918019286A GILEAD SCIENCES INC Polycyclic-Carbamoylpyridone Compounds And Their Pharmaceutical Use
Dec, 2033

(11 years from now)

IN352932B GILEAD SCIENCES INC Polycyclic Carbamoylpyridone Compounds And Their Pharmaceutical Use
Dec, 2033

(11 years from now)

EP3067358A1 GILEAD SCIENCES INC Polycyclic-Carbamoylpyridone Compounds And Their Pharmaceutical Use
Dec, 2033

(11 years from now)

EP3608325A1 GILEAD SCIENCES INC Polycyclic-Carbamoylpyridone Compounds And Their Pharmaceutical Use
Dec, 2033

(11 years from now)

EP3067358B1 GILEAD SCIENCES INC Polycyclic-Carbamoylpyridone Compounds And Their Pharmaceutical Use
Dec, 2033

(11 years from now)

EP3608325B1 GILEAD SCIENCES INC Polycyclic-Carbamoylpyridone Compounds And Their Pharmaceutical Use
Dec, 2033

(11 years from now)

EP2822954A1 GILEAD SCIENCES INC Polycyclic-Carbamoylpyridone Compounds And Their Pharmaceutical Use
Dec, 2033

(11 years from now)

EP2822954B1 GILEAD SCIENCES INC Polycyclic-Carbamoylpyridone Compounds And Their Pharmaceutical Use
Dec, 2033

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate Feb, 2033

(10 years from now)

US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate Feb, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 30MG BASE;120MG;EQ 15MG BASE TABLET;ORAL Prescription
EQ 50MG BASE;200MG;EQ 25MG BASE TABLET;ORAL Prescription

14. Drug name - BONJESTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089489 DUCHESNAY Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof Feb, 2033

(10 years from now)

US9375404 DUCHESNAY Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof Feb, 2033

(10 years from now)

US9526703 DUCHESNAY Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof Feb, 2033

(10 years from now)

US9937132 DUCHESNAY Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof Feb, 2033

(10 years from now)

Drugs and Companies using DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE ingredient

Treatment: Treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG;20MG TABLET, EXTENDED RELEASE;ORAL Prescription

15. Drug name - BRAFTOVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9474754 ARRAY BIOPHARMA INC Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor Aug, 2033

(10 years from now)

Drugs and Companies using ENCORAFENIB ingredient

Treatment: Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
50MG CAPSULE;ORAL Discontinued
75MG CAPSULE;ORAL Prescription

16. Drug name - BYFAVO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9561236 ACACIA Dosing regimen for sedation with CNS 7056 (Remimazolam) Apr, 2033

(10 years from now)

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE/VIAL POWDER;INTRAVENOUS Prescription

17. Drug name - CABOMETYX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9724342 EXELIXIS INC C-met modulator pharmaceutical compositions Jul, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription
EQ 40MG BASE TABLET;ORAL Prescription
EQ 60MG BASE TABLET;ORAL Prescription

18. Drug name - CARNEXIV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582 LUNDBECK PHARMS LLC Alkylated cyclodextrin compositions and processes for preparing and using the same Feb, 2033

(10 years from now)

Drugs and Companies using CARBAMAZEPINE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
200MG/20ML (10MG/ML) SOLUTION;INTRAVENOUS Discontinued

19. Drug name - CEQUA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10441630 SUN PHARM Topical formulations and uses thereof Aug, 2033

(10 years from now)

US8980839 SUN PHARM Topical aqueous nanomicellar, ophthalmic solutions and uses thereof Aug, 2033

(10 years from now)

US9937225 SUN PHARM Topical formulations and uses thereof Aug, 2033

(10 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.09% SOLUTION;OPHTHALMIC Prescription

20. Drug name - CLOROTEKAL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9504666 B BRAUN MEDICAL INC Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration Dec, 2033

(11 years from now)

More Information on Dosage
Strength Dosage Availability
50MG/5ML (10MG/ML) SOLUTION;INTRATHECAL Prescription

21. Drug name - COMPLERA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857102 GILEAD SCIENCES INC Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate Jan, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
200MG;EQ 25MG BASE;300MG TABLET;ORAL Prescription

22. Drug name - CONTRAVE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10403170 NALPROPION Methods of treating overweight and obesity Jun, 2033

(10 years from now)

US11139056 NALPROPION Methods of treating overweight and obesity Jun, 2033

(10 years from now)

US9633575 NALPROPION Methods of treating overweight and obesity Jun, 2033

(10 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: For chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
90MG;8MG TABLET, EXTENDED RELEASE;ORAL Prescription

23. Drug name - CYTALUX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9061057 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(10 years from now)

US9333270 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(10 years from now)

US9341629 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(10 years from now)

US9789208 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(10 years from now)

US10881747 ON TARGET LABS Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
Aug, 2033

(10 years from now)

US9254341 ON TARGET LABS Methods of manufacture of pteroyl-amino acid-fluorescent dyes
Oct, 2033

(11 years from now)

CN105492905A ON TARGET LABS Fluorescent Imaging Of Inflammatory Disease
Aug, 2033

(10 years from now)

CN105492905B ON TARGET LABS Fluorescent Imaging Of Inflammatory Disease
Aug, 2033

(10 years from now)

CN105228628A ON TARGET LABS Synthesis And Composition Of Amino Acids Connection Base Used For Compound Conjugated With The Tumour-Targeted Imaging
Aug, 2033

(10 years from now)

CN105228628B ON TARGET LABS Synthesis And Composition Of Amino Acid Is Connected To The Compound Used For The Tumour-Targeted Imaging Of The Conjugated
Aug, 2033

(10 years from now)

IN364483B ON TARGET LABS Pteroyl Ligands With Near-Infared Fluoresence Probes And Method Of Uses Thereof
Aug, 2033

(10 years from now)

IN201508446P1 ON TARGET LABS Synthesis And Composition Of Amino Acid Linking Groups Conjugated To Compounds Used For The Targeted Imaging Of Tumors
Aug, 2033

(10 years from now)

EP2968335A1 ON TARGET LABS Synthesis And Composition Of Amino Acid Linking Groups Conjugated To Compounds Used For The Targeted Imaging Of Tumors
Aug, 2033

(10 years from now)

EP2968335A4 ON TARGET LABS Synthesis And Composition Of Amino Acid Linking Groups Conjugated To Compounds Used For The Targeted Imaging Of Tumors
Aug, 2033

(10 years from now)

EP2968335B1 ON TARGET LABS Synthesis And Composition Of Amino Acid Linking Groups Conjugated To Compounds Used For The Targeted Imaging Of Tumors
Aug, 2033

(10 years from now)

EP2968614A1 ON TARGET LABS Methods Of Manufacture And Synthesis Of Amino Acid Linking Groups Conjugated To Compounds Used For Targeted Imaging Of Tumors
Oct, 2033

(11 years from now)

EP2968614A4 ON TARGET LABS Methods Of Manufacture And Synthesis Of Amino Acid Linking Groups Conjugated To Compounds Used For Targeted Imaging Of Tumors
Oct, 2033

(11 years from now)

EP2968614B1 ON TARGET LABS Methods Of Manufacture And Synthesis Of Amino Acid Linking Groups Conjugated To Compounds Used For Targeted Imaging Of Tumors
Oct, 2033

(11 years from now)

EP2972320A1 ON TARGET LABS Methods Of Imaging Inflammatory Diseases By Ligands Conjugated To Fluorescent Compounds
Dec, 2033

(11 years from now)

EP2972320A4 ON TARGET LABS Methods Of Imaging Inflammatory Diseases By Ligands Conjugated To Fluorescent Compounds
Dec, 2033

(11 years from now)

EP2972320B1 ON TARGET LABS Methods Of Imaging Inflammatory Diseases By Ligands Conjugated To Fluorescent Compounds
Dec, 2033

(11 years from now)

Drugs and Companies using PAFOLACIANINE SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 3.2MG BASE/1.6ML (EQ 2MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

24. Drug name - DAPTOMYCIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357535 HOSPIRA INC Daptomycin formulations and uses thereof Sep, 2033

(10 years from now)

US9655946 HOSPIRA INC Daptomycin formulations and uses thereof Sep, 2033

(10 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Treatment: Treatment of complicated skin and skin structure infections and s. aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by reconstituting and administering the formulation as recited in claim 12; Treatment of complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by administering the formulation of daptomycin as recited in claim 18

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
350MG/VIAL POWDER;INTRAVENOUS Prescription
500MG/VIAL POWDER;INTRAVENOUS Prescription

25. Drug name - DESCOVY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate Feb, 2033

(10 years from now)

US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate Feb, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
120MG;EQ 15MG BASE TABLET;ORAL Prescription
200MG;EQ 25MG BASE TABLET;ORAL Prescription

26. Drug name - DOCETAXEL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9763880 SHILPA Non-aqueous taxane formulations and methods of using the same Sep, 2033

(10 years from now)

US8940786 SHILPA Non-aqueous taxane nanodispersion formulations and methods of using the same Sep, 2033

(10 years from now)

US9308195 SHILPA Non-aqueous taxane formulations and methods of using the same Sep, 2033

(10 years from now)

Drugs and Companies using DOCETAXEL ingredient

Treatment: Treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy; treatment of patients with locally advanced squamous cell carcinoma of the head and neck in combination with cisplatin and fluorouracil; use in combination with doxorubicin and cyclophosphamide for adjuvant treatment of patients with operable node-positive breast cancer; treatment of patients with locally advanced metastatic breast cancer after failure of prior chemotherapy; use in combination with cisplatin for treatment of unresectable, locally advanced or metastatic non-small cell lung cancer without prior chemotherapy treatment; treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer in combination with prednisone; treatment of advanced gastric adenocarcinoma in combination with cisplatin and fluorouracil in patients that have not received prior chemotherapy; Method of administering an ethanol-free taxane liquid nanodispersion formulation to a subject combining the formulation with an aqueous medium to provide an ethanol-free taxane diluted solution

Dosage: INJECTABLE;INJECTION

More Information on Dosage
Strength Dosage Availability
20MG/ML (20MG/ML) INJECTABLE;INJECTION Prescription
80MG/4ML (20MG/ML) INJECTABLE;INJECTION Prescription
160MG/8ML (20MG/ML) INJECTABLE;INJECTION Prescription

27. Drug name - EMPAVELI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10125171 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
Aug, 2033

(10 years from now)

US10035822 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(11 years from now)

US10875893 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(11 years from now)

CN105051057B APELLIS PHARMS Cell Reactivity, Release Or Targeting Of Compstatin Analogs And Related Compositions And Methods
Nov, 2033

(11 years from now)

CN105051057A APELLIS PHARMS Cell Reactive, Long-Acting Or Targeting Camp Statin Analogue And Related Composition And Method
Nov, 2033

(11 years from now)

IN363846B APELLIS PHARMS Cell-Reactive, Long-Acting, Or Targeted Compstatin Analogs And Related Compositions And Methods
Nov, 2033

(11 years from now)

IN201505048P1 APELLIS PHARMS Cell- Reactive , Long -Acting ,Or Targeted Compstatin Analogs And Related Compositions And Methods
Nov, 2033

(11 years from now)

EP2920201A4 APELLIS PHARMS Cell-Reactive, Long-Acting, Or Targeted Compstatin Analogs And Related Compositions And Methods
Nov, 2033

(11 years from now)

EP3660033B1 APELLIS PHARMS Long-Acting Compstatin Analogs And Related Compositions And Methods
Nov, 2033

(11 years from now)

EP2920201B1 APELLIS PHARMS Long-Acting Compstatin Analogs And Related Compositions And Methods
Nov, 2033

(11 years from now)

EP3660033B9 APELLIS PHARMS Long-Acting Compstatin Analogs And Related Compositions And Methods
Nov, 2033

(11 years from now)

EP2920201A2 APELLIS PHARMS Long-Acting Compstatin Analogs And Related Compositions And Methods
Nov, 2033

(11 years from now)

EP3660033A1 APELLIS PHARMS Long-Acting Compstatin Analogs And Related Compositions And Methods
Nov, 2033

(11 years from now)

Drugs and Companies using PEGCETACOPLAN ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
1080MG/20ML (54MG/ML) SOLUTION;SUBCUTANEOUS Prescription

28. Drug name - ENTRESTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11135192 NOVARTIS PHARMS CORP Inhibitors for treating diseases characterized by atrial enlargement or remodeling Aug, 2033

(10 years from now)

US9517226 NOVARTIS PHARMS CORP Inhibitors for treating diseases characterized by atrial enlargement or remodeling Aug, 2033

(10 years from now)

US9937143 NOVARTIS PHARMS CORP Inhibitors for treating diseases characterized by atrial enlargement or remodeling Aug, 2033

(10 years from now)

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

Treatment: Treatment of heart failure with preserved ejection fraction

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
24MG;26MG TABLET;ORAL Prescription
49MG;51MG TABLET;ORAL Prescription
97MG;103MG TABLET;ORAL Prescription

29. Drug name - EPANOVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9050309 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Jan, 2033

(10 years from now)

IN201406125P1 ASTRAZENECA Dpa-Enriched Compositions Of Omega-3 Polyunsaturated Fatty Acids In Free Acid Form
Jan, 2033

(10 years from now)

IN344039B ASTRAZENECA Dpa Enriched Compositions Of Omega 3 Polyunsaturated Fatty Acids In Free Acid Form
Jan, 2033

(10 years from now)

EP2800563A4 ASTRAZENECA Dpa-Enriched Compositions Of Omega-3 Polyunsaturated Fatty Acids In Free Acid Form
Jan, 2033

(10 years from now)

EP2800563B1 ASTRAZENECA Dpa-Enriched Compositions Of Omega-3 Polyunsaturated Fatty Acids In Free Acid Form
Jan, 2033

(10 years from now)

EP2800563A1 ASTRAZENECA Dpa-Enriched Compositions Of Omega-3 Polyunsaturated Fatty Acids In Free Acid Form
Jan, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117844 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form Jan, 2033

(10 years from now)

US9050308 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form Jan, 2033

(10 years from now)

Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient

Treatment: Treatment of severe hypertriglyceridemia (500 mg/dl) in adult patients as an adjunct to diet; Treatment of hypertriglyceridemia

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS CAPSULE;ORAL Discontinued

30. Drug name - EPCLUSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8575135

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds May, 2033

(10 years from now)

US8921341

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds May, 2033

(10 years from now)

US8940718

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds May, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
200MG;50MG TABLET;ORAL Prescription
400MG;100MG TABLET;ORAL Prescription

31. Drug name - ERLEADA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9481663 JANSSEN BIOTECH Crystalline forms of an androgen receptor modulator
Jun, 2033

(10 years from now)

EP3348553A1 JANSSEN BIOTECH Crystalline Forms Of An Androgen Receptor Modulator
Jun, 2033

(10 years from now)

EP3348553B1 JANSSEN BIOTECH Crystalline Forms Of An Androgen Receptor Modulator
Jun, 2033

(10 years from now)

EP2858985B1 JANSSEN BIOTECH Crystalline Forms Of An Androgen Receptor Modulator
Jun, 2033

(10 years from now)

EP2858985A4 JANSSEN BIOTECH Crystalline Forms Of An Androgen Receptor Modulator
Jun, 2033

(10 years from now)

EP2858985A1 JANSSEN BIOTECH Crystalline Forms Of An Androgen Receptor Modulator
Jun, 2033

(10 years from now)

EP3533792B1 JANSSEN BIOTECH Crystalline Forms Of An Androgen Receptor Modulator
Jun, 2033

(10 years from now)

EP3533792A1 JANSSEN BIOTECH Crystalline Forms Of An Androgen Receptor Modulator
Jun, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10849888 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer Sep, 2033

(10 years from now)

US10052314 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer Sep, 2033

(10 years from now)

US9884054 JANSSEN BIOTECH Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer Sep, 2033

(10 years from now)

Drugs and Companies using APALUTAMIDE ingredient

Treatment: Treatment in combination with orchiectomy of non-metastatic, castration-resistant prostate cancer (nmcrpc); Treatment in combination with a gnrh agonist of non-metastatic, castration-resistant prostate cancer (nm-crpc); treatment in combination with a gnrh agonist of high risk non-metastatic, castration-resistant prostate cancer (nm-crpc); Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
60MG TABLET;ORAL Prescription

32. Drug name - ESBRIET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778947 GENENTECH INC Methods of administering pirfenidone therapy Aug, 2033

(10 years from now)

Drugs and Companies using PIRFENIDONE ingredient

Treatment: Dose reduction of pirfenidone by about one half during concurrent administration of ciprofloxacin at a dose of 750 mg twice daily (1500 mg/day) to reduce drug interactions in treatment of a fibrotic, inflammatory, or autoimmune disorder; administration of pirfenidone and avoiding concurrent administration of ciprofloxacin at a dose of 750 mg to reduce drug interactions in treatment of a fibrotic, inflammatory, or autoimmune disorder

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
267MG CAPSULE;ORAL Prescription

33. Drug name - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8829054 HQ SPCLT PHARMA Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container Mar, 2033

(10 years from now)

US8835505 HQ SPCLT PHARMA Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container Mar, 2033

(10 years from now)

Drugs and Companies using ESMOLOL HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
2GM/100ML (20MG/ML) SOLUTION;INTRAVENOUS Prescription
2.5GM/250ML (10MG/ML) SOLUTION;INTRAVENOUS Prescription

34. Drug name - EVOMELA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582 ACROTECH Alkylated cyclodextrin compositions and processes for preparing and using the same Feb, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE/VIAL POWDER;INTRAVENOUS Prescription

35. Drug name - EVRYSDI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9586955 GENENTECH INC Compounds for treating spinal muscular atrophy
Feb, 2033

(10 years from now)

CN104349777B GENENTECH INC For Compound For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

CN104349777A GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

EP2812004B1 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

EP2812004A2 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

EP2812004A4 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

EP3406252A1 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

EP3406252B1 GENENTECH INC Compounds For Treating Spinal Muscular Atrophy
Feb, 2033

(10 years from now)

Drugs and Companies using RISDIPLAM ingredient

Treatment: NA

Dosage: FOR SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
0.75MG/ML FOR SOLUTION;ORAL Prescription

36. Drug name - EYSUVIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11219596 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications May, 2033

(10 years from now)

US10857096 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications May, 2033

(10 years from now)

US10945948 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications May, 2033

(10 years from now)

US10940108 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications May, 2033

(10 years from now)

US9532955 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus May, 2033

(10 years from now)

US9737491 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus May, 2033

(10 years from now)

US9056057 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus May, 2033

(10 years from now)

US9827191 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications May, 2033

(10 years from now)

US10058511 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus May, 2033

(10 years from now)

US10993908 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications May, 2033

(10 years from now)

US10688045 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications May, 2033

(10 years from now)

US9393213 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus May, 2033

(10 years from now)

US10646436 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications May, 2033

(10 years from now)

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Treatment: A method for treating dry eye in a patient; A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; Administration to the eye of a patient for treatment of dry eye condition

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.25% SUSPENSION/DROPS;OPHTHALMIC Prescription

37. Drug name - FINTEPLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549909 ZOGENIX INC Method for the treatment of dravet syndrome May, 2033

(10 years from now)

US10478441 ZOGENIX INC Method for the treatment of Dravet syndrome May, 2033

(10 years from now)

US9610260 ZOGENIX INC Method for the treatment of Dravet Syndrome May, 2033

(10 years from now)

US9603814 ZOGENIX INC Method for the treatment of Dravet syndrome May, 2033

(10 years from now)

US10478442 ZOGENIX INC Method for the treatment of Dravet Syndrome May, 2033

(10 years from now)

US9603815 ZOGENIX INC Method for the treatment of Dravet syndrome May, 2033

(10 years from now)

Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient

Treatment: Use in combination with stiripentol, valproate, and clobazam for the treatment of seizures associated with dravet syndrome; Use in combination with stiripentol for the treatment of seizures associated with dravet syndrome

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.2MG BASE/ML SOLUTION;ORAL Prescription

38. Drug name - GENVOYA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate Feb, 2033

(10 years from now)

US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate Feb, 2033

(10 years from now)

US10039718

(Pediatric)

GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent Apr, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
150MG;150MG;200MG;EQ 10MG BASE TABLET;ORAL Prescription

39. Drug name - GIVLAARI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10125364 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
Mar, 2033

(10 years from now)

US9133461 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene
May, 2033

(10 years from now)

CN104540948A ALNYLAM PHARMS INC Composition And Method For Inhibiting The Expression Of The Alas1
Apr, 2033

(10 years from now)

CN109112131B ALNYLAM PHARMS INC Composition And Method For Inhibiting Alas1 Gene Expression
Apr, 2033

(10 years from now)

CN109112131A ALNYLAM PHARMS INC Composition And Method For Inhibiting The Expression Of The Alas1
Apr, 2033

(10 years from now)

CN104540948B ALNYLAM PHARMS INC Composition And Method For Inhibiting The Expression Of The Alas1
Apr, 2033

(10 years from now)

IN371332B ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of The Alas1 Gene
Apr, 2033

(10 years from now)

IN201407093P4 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of The Alas1 Gene
Apr, 2033

(10 years from now)

EP2836595A2 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of The Alas1 Gene
Apr, 2033

(10 years from now)

EP2836595B1 ALNYLAM PHARMS INC Compositions And Methods For Inhibiting Expression Of The Alas1 Gene
Apr, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9631193 ALNYLAM PHARMS INC Compositions and methods for inhibiting expression of the ALAS1 gene Mar, 2033

(10 years from now)

Drugs and Companies using GIVOSIRAN SODIUM ingredient

Treatment: Treatment of acute hepatic porphyria

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 189MG BASE/ML (EQ 189MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

40. Drug name - HARVONI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393256

(Pediatric)

GILEAD SCIENCES INC Methods for treating HCV Mar, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
45MG;200MG TABLET;ORAL Prescription
90MG;400MG TABLET;ORAL Prescription

41. Drug name - HETLIOZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10945988 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US9549913 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US10449176 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US9060995 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US10149829 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

USRE46604 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US9855241 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US9539234 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US10610510 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US10980770 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: Treatment of non-24 hour sleep-wake disorder by administering tasimelteon; Treatment of non-24-hour sleep-wake disorder; Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with fluvoxamine; Treatment of non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors; treatment of nighttime sleep disturbances in smith-magenis syndrome non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors; Treatment of non-24 hour sleep-wake disorder by orally administering 20mg of tasimelteon once daily before bedtime; Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon to patients with a smoking history; treatment of non-24 hour sleep-wake disorder by administering tasimelteon to patients with a smoking history; Treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG CAPSULE;ORAL Prescription

42. Drug name - HETLIOZ LQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10980770 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US10610510 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US9539234 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

US10149829 VANDA PHARMS INC Treatment of circadian rhythm disorders Jan, 2033

(10 years from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: Treatment of nighttime sleep disturbances in smith-magenissyndrome by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon to patients with a smoking history; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor; Treatment of nighttime sleep disturbances in smith-magenis syndrome non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
4MG/ML SUSPENSION;ORAL Prescription

43. Drug name - ICLUSIG

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9493470 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(11 years from now)

US11192897 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11192895 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Dec, 2033

(11 years from now)

Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient

Treatment: A method for treating philadelphia chromosome positive acute lymphoblastic leukemia; a method for treating leukemia resulting from a mutation in the bcr-abl kinase domain; a method for treating chronic myeloid leukemia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE TABLET;ORAL Prescription
EQ 15MG BASE TABLET;ORAL Prescription
EQ 30MG BASE TABLET;ORAL Prescription
EQ 45MG BASE TABLET;ORAL Prescription

44. Drug name - IDHIFA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9512107 CELGENE CORP Therapeutically active compositions and their methods of use
Jan, 2033

(10 years from now)

CN108912066B CELGENE CORP Treating Active Compound And Using Method Thereof
Jan, 2033

(10 years from now)

CN104114543A CELGENE CORP Therapy Active Compound And Using Method Thereof
Jan, 2033

(10 years from now)

CN107417667A CELGENE CORP Therapy Active Compound And Using Method Thereof
Jan, 2033

(10 years from now)

CN107417667B CELGENE CORP Therapeutically Active Compounds And Methods Of Use Thereof
Jan, 2033

(10 years from now)

CN104114543B CELGENE CORP Therapeutically Active Compound And Its Using Method
Jan, 2033

(10 years from now)

CN108912066A CELGENE CORP A Therapeutically Active Compound And Using Method Thereof
Jan, 2033

(10 years from now)

EP3406608A1 CELGENE CORP Therapeutically Active Compounds And Their Methods Of Use
Jan, 2033

(10 years from now)

EP3406608B8 CELGENE CORP Therapeutically Active Compounds And Their Methods Of Use
Jan, 2033

(10 years from now)

EP2800743A1 CELGENE CORP Therapeutically Active Compounds And Their Methods Of Use
Jan, 2033

(10 years from now)

EP2800743B1 CELGENE CORP Therapeutically Active Compounds And Their Methods Of Use
Jan, 2033

(10 years from now)

EP3406608B1 CELGENE CORP Therapeutically Active Compounds And Their Methods Of Use
Jan, 2033

(10 years from now)

EP2800743A4 CELGENE CORP Therapeutically Active Compounds And Their Methods Of Use
Jan, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10294215 CELGENE CORP Therapeutically active compounds and their methods of use Jan, 2033

(10 years from now)

Drugs and Companies using ENASIDENIB MESYLATE ingredient

Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription

45. Drug name - IMBRUVICA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10125140 PHARMACYCLICS INC Crystalline forms of a bruton's tyrosine kinase inhibitor
Jun, 2033

(10 years from now)

US9725455 PHARMACYCLICS INC Crystalline forms of a bruton's tyrosine kinase inhibitor
Jun, 2033

(10 years from now)

US10106548 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Jun, 2033

(10 years from now)

US9296753 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor
Oct, 2033

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10294231 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor Jun, 2033

(10 years from now)

US10961251 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor Jun, 2033

(10 years from now)

US10752634 PHARMACYCLICS INC Crystalline forms of a brutons tyrosine kinase inhibitor Jun, 2033

(10 years from now)

US10294232 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor Jun, 2033

(10 years from now)

US9713617 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor Jun, 2033

(10 years from now)

US9540382 PHARMACYCLICS INC Crystalline forms of a Bruton's tyrosine kinase inhibitor Aug, 2033

(10 years from now)

Drugs and Companies using IBRUTINIB ingredient

Treatment: Treatment of marginal zone lymphoma; treatment of mantle cell lymphoma; treatment of chronic lymphocytic leukemia; treatment of small lymphocytic lymphoma; treatment of waldenstrom's macroglobulinemia; treatment of chronic lymphocytic leukemia

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
70MG CAPSULE;ORAL Prescription
140MG CAPSULE;ORAL Prescription

46. Drug name - IMVEXXY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11123283 THERAPEUTICSMD INC Soluble estradiol capsule for vaginal insertion Jun, 2033

(10 years from now)

US10471072 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods Jun, 2033

(10 years from now)

US11065197 THERAPEUTICSMD INC Soluble estradiol capsule for vaginal insertion Jun, 2033

(10 years from now)

US10888516 THERAPEUTICSMD INC Soluble estradiol capsule for vaginal insertion Jun, 2033

(10 years from now)

US11116717 THERAPEUTICSMD INC Soluble estradiol capsule for vaginal insertion Jun, 2033

(10 years from now)

US10668082 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods Jun, 2033

(10 years from now)

US10568891 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods Jun, 2033

(10 years from now)

US10398708 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods Dec, 2033

(11 years from now)

US9180091 THERAPEUTICSMD INC Soluble estradiol capsule for vaginal insertion Dec, 2033

(11 years from now)

US10258630 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods Dec, 2033

(11 years from now)

Drugs and Companies using ESTRADIOL ingredient

Treatment: Treatment of a symptom of vulvar and vaginal atrophy; treatment of dyspareunia; Treatment of dyspareunia; treatment of a symptom of vulvar and vaginal atrophy; Treatment of a symptom of vulvar and vaginal atrophy; treatment of moderate to severe dyspareunia

Dosage: INSERT;VAGINAL

More Information on Dosage
Strength Dosage Availability
0.004MG INSERT;VAGINAL Prescription
0.01MG INSERT;VAGINAL Prescription

47. Drug name - INFUGEM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9241948 SUN PHARM Ready to be infused gemcetabine solution Jul, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 1200MG BASE/120ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 1300MG BASE/130ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 1400MG BASE/140ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 1500MG BASE/150ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 1600MG BASE/160ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 1700MG BASE/170ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 1800MG BASE/180ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 1900MG BASE/190ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 2000MG BASE/200ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription
EQ 2200MG BASE/220ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

48. Drug name - INVELTYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393213 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus May, 2033

(10 years from now)

US10646437 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications May, 2033

(10 years from now)

US10688045 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications May, 2033

(10 years from now)

US9056057 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus May, 2033

(10 years from now)

US9532955 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus May, 2033

(10 years from now)

US10058511 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus May, 2033

(10 years from now)

US11219597 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications May, 2033

(10 years from now)

US10864219 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications May, 2033

(10 years from now)

US9827191 KALA PHARMS INC Compositions and methods for ophthalmic and/or other applications May, 2033

(10 years from now)

US9737491 KALA PHARMS INC Nanocrystals, compositions, and methods that aid particle transport in mucus May, 2033

(10 years from now)

Drugs and Companies using LOTEPREDNOL ETABONATE ingredient

Treatment: A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; A method of reducing post-surgical pain following ocular surgery; a method of treating postoperative inflammation following ocular surgery; A method for treating ocular inflammation; A method for treating inflammation and/or other disorders in an eye of a patient

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
1% SUSPENSION/DROPS;OPHTHALMIC Prescription

49. Drug name - IONSYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9095706 THE MEDICINES CO Self-test for analgesic product Feb, 2033

(10 years from now)

Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
EQ 40MCG BASE/ACTIVATION SYSTEM;IONTOPHORESIS, TRANSDERMAL Discontinued

50. Drug name - JENTADUETO XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9555001 BOEHRINGER INGELHEIM Pharmaceutical composition and uses thereof Mar, 2033

(10 years from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes in patients with insufficient glycemic control despite therapy with one or more conventional antihyperglycemic agents by administering linagliptin in combination with metformin; method of treating type 2 diabetes in patients who have not been previously treated with an antihyperglycemic agent by administering linagliptin in combination with metformin

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription

51. Drug name - KALYDECO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8883206 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof Feb, 2033

(10 years from now)

US10272046 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof Feb, 2033

(10 years from now)

Drugs and Companies using IVACAFTOR ingredient

Treatment: Treatment of cf in a patient age 6 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 10272046; treatment of cf in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 10272046

Dosage: GRANULE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG/PACKET GRANULE;ORAL Prescription
50MG/PACKET GRANULE;ORAL Prescription
75MG/PACKET GRANULE;ORAL Prescription

52. Drug name - KENGREAL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8680052 CHIESI Methods of treating, reducing the incidence of, and/or preventing ischemic events Mar, 2033

(10 years from now)

Drugs and Companies using CANGRELOR ingredient

Treatment: Method comprising iv administration of cangrelor before pci then continuous infusion for at least 2 hours or the duration of pci and, during or after continuous infusion, administration of a loading dose of ticagrelor, or an equivalent method

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50MG/VIAL POWDER;INTRAVENOUS Prescription

53. Drug name - KORLYM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10500216 CORCEPT THERAP Optimizing mifepristone absorption Mar, 2033

(10 years from now)

Drugs and Companies using MIFEPRISTONE ingredient

Treatment: Treating cushing's syndrome

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
300MG TABLET;ORAL Prescription

54. Drug name - KYPROLIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582 ONYX THERAP Alkylated cyclodextrin compositions and processes for preparing and using the same Feb, 2033

(10 years from now)

Drugs and Companies using CARFILZOMIB ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
10MG/VIAL POWDER;INTRAVENOUS Prescription
30MG/VIAL POWDER;INTRAVENOUS Prescription
60MG/VIAL POWDER;INTRAVENOUS Prescription

55. Drug name - LILETTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090186 MEDICINES360 Methods for using intrauterine systems and IUD insertion devices Oct, 2033

(11 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Treatment: A method for prevention of pregnancy

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage
Strength Dosage Availability
52MG INTRAUTERINE DEVICE;INTRAUTERINE Prescription

56. Drug name - LINZESS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9708371 ALLERGAN Treatments for gastrointestinal disorders Aug, 2033

(10 years from now)

Drugs and Companies using LINACLOTIDE ingredient

Treatment: Method of treating irritable bowel syndrome with constipation in adult patients.; method of treating chronic idiopathic constipation in adult patients.

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
72MCG CAPSULE;ORAL Prescription
145MCG CAPSULE;ORAL Prescription
290MCG CAPSULE;ORAL Prescription

57. Drug name - LOKELMA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10695365 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(11 years from now)

US8877255 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(11 years from now)

US9913860 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(11 years from now)

CN104797263A ASTRAZENECA Microporous Zirconium Silicate For Treating Hyperpotassaemia
Oct, 2033

(11 years from now)

CN104797263B ASTRAZENECA For Curing Hyperpotassaemia Microporous Zirconium Silicate
Oct, 2033

(11 years from now)

More Information on Dosage
Strength Dosage Availability
5GM/PACKET FOR SUSPENSION;ORAL Prescription
10GM/PACKET FOR SUSPENSION;ORAL Prescription

58. Drug name - LONHALA MAGNAIR KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9604018 SUNOVION RESP Aerosol therapy device May, 2033

(10 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: NA

Dosage: SOLUTION;INHALATION

More Information on Dosage
Strength Dosage Availability
25MCG/ML SOLUTION;INHALATION Prescription

59. Drug name - LORBRENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8680111 PFIZER Macrocyclic derivatives for the treatment of diseases
Mar, 2033

(10 years from now)

CN104169286A PFIZER Macrocyclic Derivative For Treating Proliferative Diseases
Feb, 2033

(10 years from now)

CN104169286B PFIZER Macrocyclic Derivative For Treating Proliferative Diseases
Feb, 2033

(10 years from now)

IN201407205P4 PFIZER Macrocyclic Derivatives For The Treatment Of Proliferative Diseases
Feb, 2033

(10 years from now)

IN298989B PFIZER Macrocyclic Derivatives For The Treatment Of Proliferative Diseases
Feb, 2033

(10 years from now)

EP2822953B1 PFIZER Macrocyclic Derivatives For The Treatment Of Proliferative Diseases
Feb, 2033

(10 years from now)

EP2822953B9 PFIZER Macrocyclic Derivatives For The Treatment Of Proliferative Diseases
Feb, 2033

(10 years from now)

EP2822953A1 PFIZER Macrocyclic Derivatives For The Treatment Of Proliferative Diseases
Feb, 2033

(10 years from now)

Drugs and Companies using LORLATINIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
25MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription

60. Drug name - LUZU

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9453006 BAUSCH Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient
Sep, 2033

(10 years from now)

US9199977 BAUSCH Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
Sep, 2033

(10 years from now)

US9012484 BAUSCH Crystal and pharmaceutical preparation containing the same crystal
Sep, 2033

(10 years from now)

CN105026390A BAUSCH Crystal Form With Specific Crystallization Habit Modifier And Drug Composition Containing Crystal Form As Active Ingredient
Jun, 2033

(10 years from now)

CN105026390B BAUSCH Crystal Form With Specific Crystallization Habit Modifier And Drug Composition Containing Crystal Form As Active Ingredient
Jun, 2033

(10 years from now)

EP2964641B1 BAUSCH Crystalline Form Having Specific Crystal Habit And Pharmaceutical Composition Containing This Crystalline Form As Active Ingredient
Jun, 2033

(10 years from now)

EP2964641A1 BAUSCH Crystalline Form Having Specific Crystal Habit And Pharmaceutical Composition Containing This Crystalline Form As Active Ingredient
Jun, 2033

(10 years from now)

EP2895165A1 BAUSCH Crystal And Pharmaceutical Preparation Containing The Same Crystal
Sep, 2033

(10 years from now)

EP2895165B1 BAUSCH Crystal And Pharmaceutical Preparation Containing The Same Crystal
Sep, 2033

(10 years from now)

Drugs and Companies using LULICONAZOLE ingredient

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% CREAM;TOPICAL Prescription

61. Drug name - LYMPHOSEEK KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9439985 CARDINAL HEALTH 414 Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran
Sep, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
N/A INJECTABLE;INJECTION Prescription

62. Drug name - MEKINIST

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869869 NOVARTIS Method of adjuvant cancer treatment Aug, 2033

(10 years from now)

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Treatment: Mekinist(r) is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.5MG TABLET;ORAL Prescription
EQ 1MG TABLET;ORAL Discontinued
EQ 2MG TABLET;ORAL Prescription

63. Drug name - MEKTOVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9562016 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(11 years from now)

CN104870427B ARRAY BIOPHARMA INC Preparation And Formulation Comprising An Mek Inhibitor Of Mek Inhibitors
Oct, 2033

(11 years from now)

CN104870427A ARRAY BIOPHARMA INC Preparation Of Formulation Comprising Mek Inhibitor
Oct, 2033

(11 years from now)

IN201501287P2 ARRAY BIOPHARMA INC Preparation Of And Formulation Comprising A Mek Inhibitor
Oct, 2033

(11 years from now)

IN334786B ARRAY BIOPHARMA INC Preparation Of And Formulation Comprising A Mek Inhibitor
Oct, 2033

(11 years from now)

EP2909182A4 ARRAY BIOPHARMA INC Preparation Of And Formulation Comprising A Mek Inhibitor
Oct, 2033

(11 years from now)

EP2909182A1 ARRAY BIOPHARMA INC Preparation Of And Formulation Comprising A Mek Inhibitor
Oct, 2033

(11 years from now)

EP2909182B1 ARRAY BIOPHARMA INC Preparation Of And Formulation Comprising A Mek Inhibitor
Oct, 2033

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9980944 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor Oct, 2033

(11 years from now)

US9598376 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor Oct, 2033

(11 years from now)

Drugs and Companies using BINIMETINIB ingredient

Treatment: Treatment of melanoma with a braf mutation; Method of treating melanoma

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET;ORAL Prescription

64. Drug name - MITIGARE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399036 HIKMA INTL PHARMS Methods of colchicine administration Aug, 2033

(10 years from now)

US8927607 HIKMA INTL PHARMS Methods of colchicine administration Aug, 2033

(10 years from now)

US9675613 HIKMA INTL PHARMS Methods of colchicine administration Aug, 2033

(10 years from now)

US9789108 HIKMA INTL PHARMS Methods of colchicine administration Aug, 2033

(10 years from now)

US9555029 HIKMA INTL PHARMS Methods of colchicine administration Aug, 2033

(10 years from now)

Drugs and Companies using COLCHICINE ingredient

Treatment: Method of using colchicine for the prophylaxis of gout flares

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
0.6MG CAPSULE;ORAL Prescription

65. Drug name - NAFTIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10166206 SEBELA IRELAND LTD Topical compositions and methods for making and using same Jan, 2033

(10 years from now)

US8778365 SEBELA IRELAND LTD Topical compositions and methods for making and using same Jan, 2033

(10 years from now)

US10695303 SEBELA IRELAND LTD Topical compositions and methods for making and using same Jan, 2033

(10 years from now)

US10166205 SEBELA IRELAND LTD Topical compositions and methods for making and using same Jan, 2033

(10 years from now)

US10729667 SEBELA IRELAND LTD Topical compositions and methods for making and using same Jan, 2033

(10 years from now)

US9161914 SEBELA IRELAND LTD Topical compositions and methods for making and using same Jan, 2033

(10 years from now)

Drugs and Companies using NAFTIFINE HYDROCHLORIDE ingredient

Treatment: Treatment of fungal infections

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
2% GEL;TOPICAL Prescription

66. Drug name - NOXAFIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582 MERCK SHARP DOHME Alkylated cyclodextrin compositions and processes for preparing and using the same Feb, 2033

(10 years from now)

Drugs and Companies using POSACONAZOLE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
300MG/16.7ML (18MG/ML) SOLUTION;INTRAVENOUS Prescription

67. Drug name - NURTEC ODT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8759372 BIOHAVEN IRELAND N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt
Feb, 2033

(10 years from now)

CN104136437A BIOHAVEN IRELAND N - (5S, 6S, 9R) -4-(2-Oxo-3, -2 - Dihydro - -1H - Imidazo [4, 5-B-A] Naphthyridine - -1 - Yl) - Piperidine - -1 - Carboxylic Acid 5-Amino - -6-(2, 3 Phenyl) -6, 7, 8, 9-Tetrahydropyranyl -5H - Cyclohepta [B] -9 - Ester Hemisulfate
Feb, 2033

(10 years from now)

CN104136437B BIOHAVEN IRELAND N - (5S, 6S, 9R) -4-(2-Oxo-3, -2 - Dihydro - -1H - Imidazo [4, 5-B-A] Naphthyridine - -1 - Yl) - Piperidine - -1 - Carboxylic Acid 5-Amino - -6-(2, 3 Phenyl) -6, 7, 8, 9-Tetrahydropyranyl -5H - Cyclohepta [B] -9 - Ester Hemisulfate
Feb, 2033

(10 years from now)

EP2820016B1 BIOHAVEN IRELAND N- (5S, 6S, 9R) - 5 -Amino- 6 - (2, 3 - Difluorophenyl) -6, 7, 8, 9 - Tetrahydro - 5H - Cyclohepta [B]Pyridin-9 -Yl- 4 - (2 - Oxo-2, 3 - Dihydro - 1H- Imidazo [4, 5 -B]Pyridin - 1 - Yl) Piperidine - 1 - Carboxylate, Hemisulfate Salt
Feb, 2033

(10 years from now)

EP2820016A1 BIOHAVEN IRELAND N- (5S, 6S, 9R) - 5 -Amino- 6 - (2, 3 - Difluorophenyl) -6, 7, 8, 9 - Tetrahydro - 5H - Cyclohepta [B]Pyridin-9 -Yl- 4 - (2 - Oxo-2, 3 - Dihydro - 1H- Imidazo [4, 5 -B]Pyridin - 1 - Yl) Piperidine - 1 - Carboxylate, Hemisulfate Salt
Feb, 2033

(10 years from now)

EP3254681A1 BIOHAVEN IRELAND N-(5S,6S,9R)-5-Amino-6-(2,3-Difluorophenyl)-6,7,8,9-Tetrahydro-5H-Cyclohepta[B]Pyridin-9-Yl-4-(2-Oxo-2,3-Dihydro-1H-Imidazo[4,5-B]Pyridin-1-Yl)Piperidine-1-Carboxylate Salt
Feb, 2033

(10 years from now)

EP3254681B1 BIOHAVEN IRELAND N-(5S,6S,9R)-5-Amino-6-(2,3-Difluorophenyl)-6,7,8,9-Tetrahydro-5H-Cyclohepta[B]Pyridin-9-Yl-4-(2-Oxo-2,3-Dihydro-1H-Imidazo[4,5-B]Pyridin-1-Yl)Piperidine-1-Carboxylate Salt
Feb, 2033

(10 years from now)

Drugs and Companies using RIMEGEPANT SULFATE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 75MG BASE TABLET, ORALLY DISINTEGRATING;ORAL Prescription

68. Drug name - OCALIVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10174073 INTERCEPT PHARMS INC Preparation and uses of obeticholic acid
Jun, 2033

(10 years from now)

EP3336097A1 INTERCEPT PHARMS INC Preparation Of The Non-Crystalline Form Of Obeticholic Acid
Jun, 2033

(10 years from now)

EP3336097B1 INTERCEPT PHARMS INC Preparation Of The Non-Crystalline Form Of Obeticholic Acid
Jun, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238673 INTERCEPT PHARMS INC Preparation and uses of obeticholic acid Jun, 2033

(10 years from now)

US10047117 INTERCEPT PHARMS INC Preparation and uses of obeticholic acid Sep, 2033

(10 years from now)

Drugs and Companies using OBETICHOLIC ACID ingredient

Treatment: Treatment of primary biliary cholangitis (pbc)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

69. Drug name - ODEFSEY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate Feb, 2033

(10 years from now)

US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate Feb, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
200MG;EQ 25MG BASE;EQ 25MG BASE TABLET;ORAL Prescription

70. Drug name - OMIDRIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9486406 RAYNER SURGICAL Stable preservative-free mydriatic and anti-inflammatory solutions for injection Oct, 2033

(11 years from now)

US9066856 RAYNER SURGICAL Stable preservative-free mydriatic and anti-inflammatory solutions for injection Oct, 2033

(11 years from now)

US9855246 RAYNER SURGICAL Stable preservative-free mydriatic and anti-inflammatory solutions for injection Oct, 2033

(11 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.3% BASE;EQ 1% BASE SOLUTION;IRRIGATION Prescription

71. Drug name - ONIVYDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9339497 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan Jun, 2033

(10 years from now)

US9717724 IPSEN INC Methods for treating pancreatic cancer using combination therapies Jun, 2033

(10 years from now)

US9492442 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan Jun, 2033

(10 years from now)

US9364473 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan Jun, 2033

(10 years from now)

US9452162 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan Jun, 2033

(10 years from now)

US10980795 IPSEN INC Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan Jun, 2033

(10 years from now)

Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient

Treatment: Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin, in a patient not homozygous for the ugt1a1*28 allele; treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of exocrine pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; treatment of pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin, in a patient homozygous for the ugt1a1*28 allele; Treatment of pancreatic cancer that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin

Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML) INJECTABLE, LIPOSOMAL;INTRAVENOUS Prescription

72. Drug name - ONZETRA XSAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478574 CURRAX Nasal administration Nov, 2033

(11 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: Method of delivering sumatriptan to a nasal cavity

Dosage: POWDER;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 11MG BASE POWDER;NASAL Prescription

73. Drug name - ORFADIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9301932 SWEDISH ORPHAN Liquid pharmaceutical composition comprising nitisinone Feb, 2033

(10 years from now)

Drugs and Companies using NITISINONE ingredient

Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
4MG/ML SUSPENSION;ORAL Prescription

74. Drug name - OZEMPIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335462 NOVO Use of long-acting GLP-1 peptides Jun, 2033

(10 years from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/1.5ML (1.34MG/ML) SOLUTION;SUBCUTANEOUS Prescription
4MG/3ML (1.34MG/ML) SOLUTION;SUBCUTANEOUS Prescription

75. Drug name - PEMAZYRE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10131667 INCYTE CORP Substituted tricyclic compounds as FGFR inhibitors Jun, 2033

(10 years from now)

Drugs and Companies using PEMIGATINIB ingredient

Treatment: For the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
4.5MG TABLET;ORAL Prescription
9MG TABLET;ORAL Prescription
13.5MG TABLET;ORAL Prescription

76. Drug name - PHENYLEPHRINE HYDROCHLORIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859623 PARAGON BIOTECK Methods and compositions of stable phenylephrine formulations Nov, 2033

(11 years from now)

Drugs and Companies using PHENYLEPHRINE HYDROCHLORIDE ingredient

Treatment: Dilation of the pupil

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
2.5% SOLUTION/DROPS;OPHTHALMIC Prescription
10% SOLUTION/DROPS;OPHTHALMIC Prescription

77. Drug name - PHEXXI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10568855 EVOFEM INC Compositions and methods for enhancing the efficacy of contraceptive microbicides Mar, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
1%;1.8%;0.4% GEL;VAGINAL Prescription

78. Drug name - PICATO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9789078 LEO LABS Method of topically treating actinic keratosis with ingenol mebutate cycle therapy May, 2033

(10 years from now)

Drugs and Companies using INGENOL MEBUTATE ingredient

Treatment: Topical treatment of actinic keratosis of the face or scalp using more than one treatment course of ingenol mebutate

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.015% GEL;TOPICAL Discontinued
0.05% GEL;TOPICAL Discontinued

79. Drug name - PLENVU

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9707297 SALIX Compositions Sep, 2033

(10 years from now)

US8999313 SALIX Compositions Sep, 2033

(10 years from now)

US9326969 SALIX Compositions Sep, 2033

(10 years from now)

US10918723 SALIX Colon cleansing compositions and methods of use Sep, 2033

(10 years from now)

US10016504 SALIX Compositions Sep, 2033

(10 years from now)

Drugs and Companies using ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE ingredient

Treatment: For cleansing of the colon in preparation for colonoscopy in adults

Dosage: FOR SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
7.54GM;140GM;2.2GM;48.11GM;5.2GM;9GM FOR SOLUTION;ORAL Prescription

80. Drug name - PREVYMIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603384 MERCK SHARP DOHME Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative Feb, 2033

(10 years from now)

Drugs and Companies using LETERMOVIR ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
240MG/12ML (20MG/ML) SOLUTION;INTRAVENOUS Prescription
480MG/24ML (20MG/ML) SOLUTION;INTRAVENOUS Prescription

81. Drug name - PROLENSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517220 BAUSCH AND LOMB Bromfenac bioavailability Nov, 2033

(11 years from now)

Drugs and Companies using BROMFENAC SODIUM ingredient

Treatment: Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 0.07% ACID SOLUTION/DROPS;OPHTHALMIC Prescription

82. Drug name - QBREXZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10548875 JOURNEY Glycopyrrolate salts
Feb, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259414 JOURNEY Glycopyrrolate salts Feb, 2033

(10 years from now)

US8859610 JOURNEY Crystalline glycopyrrolate tosylate Feb, 2033

(10 years from now)

US10543192 JOURNEY Glycopyrrolate salts Feb, 2033

(10 years from now)

US10004717 JOURNEY Glycopyrrolate salts Feb, 2033

(10 years from now)

Drugs and Companies using GLYCOPYRRONIUM TOSYLATE ingredient

Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older

Dosage: CLOTH;TOPICAL

More Information on Dosage
Strength Dosage Availability
EQ 2.4% BASE CLOTH;TOPICAL Prescription

83. Drug name - QELBREE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9662338 SUPERNUS PHARMS Formulations of viloxazine Feb, 2033

(10 years from now)

US9358204 SUPERNUS PHARMS Formulations of viloxazine Feb, 2033

(10 years from now)

US9603853 SUPERNUS PHARMS Formulations of viloxazine Feb, 2033

(10 years from now)

Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient

Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 150MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 200MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription

84. Drug name - QUDEXY XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8889190 UPSHER SMITH LABS Extended-release topiramate capsules Mar, 2033

(10 years from now)

US10363224 UPSHER SMITH LABS Extended-release topiramate capsules Mar, 2033

(10 years from now)

US8652527 UPSHER SMITH LABS Extended-release topiramate capsules Mar, 2033

(10 years from now)

US9555005 UPSHER SMITH LABS Extended-release topiramate capsules Mar, 2033

(10 years from now)

US9101545 UPSHER SMITH LABS Extended-release topiramate capsules Mar, 2033

(10 years from now)

Drugs and Companies using TOPIRAMATE ingredient

Treatment: Treatment of seizures

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
50MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
100MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
150MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
200MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

85. Drug name - QUILLICHEW ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103494 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet Aug, 2033

(10 years from now)

US10857143 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet Aug, 2033

(10 years from now)

US11103495 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet Aug, 2033

(10 years from now)

US9844544 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet Aug, 2033

(10 years from now)

US9295642 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet Aug, 2033

(10 years from now)

US8999386 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet Aug, 2033

(10 years from now)

US9545399 NEXTWAVE PHARMS Methylphenidate extended release chewable tablet Aug, 2033

(10 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Treatment: A method for treating a subject having adhd, said method comprising orally administering to said subject a racemic methylphenidate chewable tablet as claimed; A method of providing a subject with a therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet as claimed; A method of providing a subject with therapeutically effective amount of racemic methylphenidate by orally administering to said subject a single methylphenidate extended release chewable tablet according to claim 1

Dosage: TABLET, EXTENDED RELEASE, CHEWABLE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET, EXTENDED RELEASE, CHEWABLE;ORAL Prescription
30MG TABLET, EXTENDED RELEASE, CHEWABLE;ORAL Prescription
40MG TABLET, EXTENDED RELEASE, CHEWABLE;ORAL Prescription

86. Drug name - QULIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9850246 ABBVIE INC Process for making CGRP receptor antagonists
Mar, 2033

(10 years from now)

EP2849568A1 ABBVIE INC Process For Making Cgrp Receptor Antagonists
Mar, 2033

(10 years from now)

EP2849568B1 ABBVIE INC Process For Making Cgrp Receptor Antagonists
Mar, 2033

(10 years from now)

EP2849568A4 ABBVIE INC Process For Making Cgrp Receptor Antagonists
Mar, 2033

(10 years from now)

Drugs and Companies using ATOGEPANT ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription
60MG TABLET;ORAL Prescription

87. Drug name - REZUROCK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10696660 KADMON PHARMS LLC Rho kinase inhibitors Oct, 2033

(11 years from now)

US9815820 KADMON PHARMS LLC Rho kinase inhibitors Oct, 2033

(11 years from now)

US10183931 KADMON PHARMS LLC Rho kinase inhibitors Oct, 2033

(11 years from now)

Drugs and Companies using BELUMOSUDIL MESYLATE ingredient

Treatment: For the treatment of chronic graft versus host disease; For the treatment of chronic graft versus hold disease

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

88. Drug name - ROSZET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376470 ALTHERA PHARMS Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases May, 2033

(10 years from now)

US9763885 ALTHERA PHARMS Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases May, 2033

(10 years from now)

Drugs and Companies using EZETIMIBE; ROSUVASTATIN CALCIUM ingredient

Treatment: Treatment of hyperlipidemia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG;EQ 5MG BASE TABLET;ORAL Prescription
10MG;EQ 10MG BASE TABLET;ORAL Prescription
10MG;EQ 20MG BASE TABLET;ORAL Prescription
10MG;EQ 40MG BASE TABLET;ORAL Prescription

89. Drug name - ROZLYTREK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9085565 GENENTECH INC Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
May, 2033

(10 years from now)

CN104395308B GENENTECH INC N - [3 - (5, 5-Difluoro-Benzyl)--1H - Indazole - -3 - Yl] -4-(4-Methyl-Piperazine - -1 - Yl)--2-(Tetrahydro-Pyran - -4 - Ylamino) - Benzamide Preparation Method
May, 2033

(10 years from now)

CN104395308A GENENTECH INC N - [3 - (5, 5-Difluoro-Benzyl)--1H - Indazole - -3 - Yl] -4-(4-Methyl-Piperazine - -1 - Yl)--2-(Tetrahydro-Pyran - -4 - Ylamino) - Benzamide Preparation Method
May, 2033

(10 years from now)

IN201409107P4 GENENTECH INC Process For The Preparation Of N [5 (3 5 Difluoro Benzyl) 1H Indazol 3 Yl] 4 (4 Methyl Piperazin 1 Yl) 2 (Tetrahydro Pyran 4 Ylamino) Benzamide
May, 2033

(10 years from now)

IN361050B GENENTECH INC Process For The Preparation Of N-[5-(3-5-Difluoro Benzyl)-1H-Indazol 3 Yl]- 4-(4 Methyl Piperazin -1- Yl) -2- (Tetrahydro Pyran -4- Ylamino) Benzamide
May, 2033

(10 years from now)

EP3333166A1 GENENTECH INC Process For The Preparation Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide
May, 2033

(10 years from now)

EP3290414B1 GENENTECH INC Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide
May, 2033

(10 years from now)

EP3333166B1 GENENTECH INC Process For The Preparation Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide
May, 2033

(10 years from now)

EP3290414A1 GENENTECH INC Crystalline Form Of N-[5-(3,5-Difluoro-Benzyl)-1H-Indazol-3-Yl]-4-(4-Methyl-Piperazin-1-Yl)-2-(Tetrahydro-Pyran-4-Ylamino)-Benzamide
May, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649306 GENENTECH INC Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide May, 2033

(10 years from now)

Drugs and Companies using ENTRECTINIB ingredient

Treatment: Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; treatment of ros1-positive non-small cell lung cancer

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
100MG CAPSULE;ORAL Prescription
200MG CAPSULE;ORAL Prescription

90. Drug name - RYBELSUS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10933120 NOVO Compositions of GLP-1 peptides and preparation thereof Mar, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription
7MG TABLET;ORAL Prescription
14MG TABLET;ORAL Prescription

91. Drug name - SCEMBLIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8829195 NOVARTIS Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
May, 2033

(10 years from now)

CN104302638B NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

CN104302638A NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

CN104302634A NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

CN104302634B NOVARTIS For Inhibiting Activity Of Abl1, Abl2, And Bcr-Abl1 Of Benzamide Derivatives
May, 2033

(10 years from now)

EP2861579B9 NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

EP2861576B1 NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

EP2861579A1 NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

EP2861579B1 NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

EP2861576A1 NOVARTIS Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1
May, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription
EQ 40MG BASE TABLET;ORAL Prescription

92. Drug name - SECUADO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10022445 HISAMITSU Patch Jul, 2033

(10 years from now)

US9687474 HISAMITSU Patch Jul, 2033

(10 years from now)

US10814002 HISAMITSU Patch and method for producing the same Jul, 2033

(10 years from now)

US10583121 HISAMITSU Patch Jul, 2033

(10 years from now)

US11123305 HISAMITSU Patch Jul, 2033

(10 years from now)

Drugs and Companies using ASENAPINE ingredient

Treatment: Method of treating adults with schizophrenia comprising administering asenapine via a transdermal patch

Dosage: SYSTEM;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
3.8MG/24HR SYSTEM;TRANSDERMAL Prescription
5.7MG/24HR SYSTEM;TRANSDERMAL Prescription
7.6MG/24HR SYSTEM;TRANSDERMAL Prescription

93. Drug name - SESQUIENT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9493582 LUPIN Alkylated cyclodextrin compositions and processes for preparing and using the same Feb, 2033

(10 years from now)

Drugs and Companies using FOSPHENYTOIN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML) SOLUTION;INTRAVENOUS Discontinued
EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML) SOLUTION;INTRAVENOUS Discontinued

94. Drug name - SEYSARA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9255068 ALMIRALL Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same
Feb, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 60MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription
EQ 150MG BASE TABLET;ORAL Prescription

95. Drug name - SOAANZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10154963 SARFE PHARMS Controlled-release formulations comprising Torsemide Oct, 2033

(11 years from now)

Drugs and Companies using TORSEMIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription
60MG TABLET;ORAL Prescription

96. Drug name - STRIBILD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718

(Pediatric)

GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent Apr, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
150MG;150MG;200MG;300MG TABLET;ORAL Prescription

97. Drug name - SYMDEKO (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10058546 VERTEX PHARMS INC Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof Jul, 2033

(10 years from now)

US9012496 VERTEX PHARMS INC Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof Jul, 2033

(10 years from now)

Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient

Treatment: Treatment of cystic fibrosis in patients 12 years and older, with a f508del or g551d cftr gene mutation and a a455e, 2789+5g->a, or 3849+10kbc->t mutation, comprising concurrent coadministration of the compositions of claim 1 of u.s patent 10058546; treatment of cystic fibrosis in patients 6 years and older, with a f508del or g551d cftr gene mutation and a a455e, 2789+5g->, or 3849+10kbc->t mutation, comprising concurrent coadministration of the compositions of claim 1 of u.s. patent 10058546; treatment of cf in patients 6 years and older who have a f508del or g551d cftr mutation and a 2nd mutation selected from r117h, a455e, 2789+5g->a, and 3849+10kbc->t, comprising concurrent coadministration of the compositions of claim 1 of us 10058546; treatment of cf in patients 12 years and older who have a f508del or g551d cftr mutation and a 2nd mutation selected from r117h, a455e, 2789+5g->a, & 3849+10kbc->t, comprising concurrent coadministration of the compositions of claim 1 of us 10058546; Tezacaftor and ivacaftor for the treatment of cystic fibrosis in patients who are homozygous for the f508del mutation or heterozygous for the f508del mutation and a second mutation that is responsive to tezacaftor/ivacaftor

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
75MG;75MG, 50MG TABLET;ORAL Prescription
150MG;150MG, 100MG TABLET;ORAL Prescription

98. Drug name - SYMPROIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10952968 BDSI Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
May, 2033

(10 years from now)

EP2851075A4 BDSI Preparation Containing 6,7-Unsaturated-7-Carbamoylmorphinan Derivative
May, 2033

(10 years from now)

EP2851075B1 BDSI Preparation Containing 6,7-Unsaturated-7-Carbamoylmorphinan Derivative
May, 2033

(10 years from now)

EP2851075A1 BDSI Preparation Containing 6,7-Unsaturated-7-Carbamoylmorphinan Derivative
May, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.2MG BASE TABLET;ORAL Prescription

99. Drug name - TAFINLAR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10869869 NOVARTIS Method of adjuvant cancer treatment Aug, 2033

(10 years from now)

Drugs and Companies using DABRAFENIB MESYLATE ingredient

Treatment: Tafinlar(r) is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE CAPSULE;ORAL Prescription
EQ 75MG BASE CAPSULE;ORAL Prescription

100. Drug name - TAZVERIK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9394283 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(10 years from now)

US10821113 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor
Apr, 2033

(10 years from now)

CN104603130A EPIZYME INC Salt Forms Of Human Histone Methyltransferase Ezh2 Inhibitor
Apr, 2033

(10 years from now)

CN104603130B EPIZYME INC A Salt Form Of Histone Methyltransferase Ezh2 Inhibitor
Apr, 2033

(10 years from now)

CN108358899B EPIZYME INC Salt Form Of Human Histone Methyltransferase Ezh2 Inhibitor
Apr, 2033

(10 years from now)

CN108358899A EPIZYME INC Human Salt Form Transmethylase Ezh2 Inhibitor Of
Apr, 2033

(10 years from now)

EP2836491B1 EPIZYME INC Salt Form Of A Human Histone Methyltransferase Ezh2 Inhibitor
Apr, 2033

(10 years from now)

EP3184523A1 EPIZYME INC N-((4,6-Dimethyl-2-Oxo-L,2-Dihydropyridin-3-Yl)Methyl)-5-(Ethyl (Tetrahydro-2H-Pyran-4-Yl)Amino)-4-Methyl-4'-(Morpholinomethyl)-[L,1'-Biphenyl]-3-Carboxamide Hydrobromide For Use In The Treatment Of A Cell Proliferative Disorder Of The Hematologic System
Apr, 2033

(10 years from now)

EP2836491A4 EPIZYME INC Salt Form Of A Human Hi Stone Methyltransf Erase Ezh2 Inhibitor
Apr, 2033

(10 years from now)

EP3184523B1 EPIZYME INC N-((4,6-Dimethyl-2-Oxo-L,2-Dihydropyridin-3-Yl)Methyl)-5-(Ethyl (Tetrahydro-2H-Pyran-4-Yl)Amino)-4-Methyl-4'-(Morpholinomethyl)-[L,1'-Biphenyl]-3-Carboxamide Hydrobromide For Use In The Treatment Of A Cell Proliferative Disorder Of The Hematologic System
Apr, 2033

(10 years from now)

EP2836491A1 EPIZYME INC Salt Form Of A Human Histone Methyltransferase Ezh2 Inhibitor
Apr, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9872862 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor Apr, 2033

(10 years from now)

US10245269 EPIZYME INC Salt form of a human histone methyltransferase EZH2 inhibitor Apr, 2033

(10 years from now)

Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient

Treatment: Method of treating a lung metastasis of epithelioid sarcoma; Method of treating epithelioid sarcoma by inhibiting enhancer of zeste homolog 2 (ezh2); method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation by inhibiting ezh2; method of treating relapsed or refractory follicular lymphoma by inhibiting ezh2

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

101. Drug name - TIBSOVO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9850277 SERVIER Therapeutically active compositions and their methods of use
Jan, 2033

(10 years from now)

US9474779 SERVIER Therapeutically active compositions and their methods of use
Aug, 2033

(10 years from now)

IN338474B SERVIER Therapeutically Active Compositions And Their Methods Of Use
Jan, 2033

(10 years from now)

IN201405986P1 SERVIER Therapeutically Active Compounds And Their Methods Of Use
Jan, 2033

(10 years from now)

EP2804851B1 SERVIER Lactam Derivates Useful As Inhibitors Of Mutant Idh1
Jan, 2033

(10 years from now)

EP2804851A4 SERVIER Therapeutically Active Compounds And Their Methods Of Use
Jan, 2033

(10 years from now)

EP3447052B1 SERVIER Methods Of Preparing New Idh1 Inhibitors
Jan, 2033

(10 years from now)

EP3447052A1 SERVIER Methods Of Preparing New Idh1 Inhibitors
Jan, 2033

(10 years from now)

EP2804851A1 SERVIER Lactam Derivates Useful As Inhibitors Of Mutant Idh1
Jan, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10717764 SERVIER Therapeutically active compounds and their methods of use Jan, 2033

(10 years from now)

Drugs and Companies using IVOSIDENIB ingredient

Treatment: A method of treating previously treated, locally advanced or metastatic cholangiocarcinoma characterized by an idh1 mutation

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
250MG TABLET;ORAL Prescription

102. Drug name - TIGECYCLINE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855335 AMNEAL Tigecycline composition for injection Apr, 2033

(10 years from now)

Drugs and Companies using TIGECYCLINE ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50MG/VIAL POWDER;INTRAVENOUS Prescription

103. Drug name - TOLSURA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10463740 MAYNE PHARMA INTL Itraconazole compositions and dosage forms, and methods of using the same Jun, 2033

(10 years from now)

US9272046 MAYNE PHARMA INTL Itraconazole compositions and dosage forms, and methods of using the same Jun, 2033

(10 years from now)

US8921374 MAYNE PHARMA INTL Itraconazole compositions and dosage forms, and methods of using the same Jun, 2033

(10 years from now)

US10806792 MAYNE PHARMA INTL Itraconazole compositions and dosage forms, and methods of using the same Jun, 2033

(10 years from now)

US9713642 MAYNE PHARMA INTL Itraconazole compositions and dosage forms, and methods of using the same Jun, 2033

(10 years from now)

Drugs and Companies using ITRACONAZOLE ingredient

Treatment: Treatment of fungal infections, including blastomycosis, histoplasmosis, and aspergillosis

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
65MG CAPSULE;ORAL Prescription

104. Drug name - TRIKAFTA (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9012496 VERTEX PHARMS INC Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof Jul, 2033

(10 years from now)

Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient

Treatment: Treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with a composition comprising elexacaftor, tezacaftor, and ivacaftor; and another composition comprising ivacaftor; treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene with a composition comprising elexacaftor, tezacaftor, and ivacaftor; and another composition comprising ivacaftor

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG,37.5MG,25MG; 75MG TABLET;ORAL Prescription
100MG,75MG,50MG; 150MG TABLET;ORAL Prescription

105. Drug name - TRUDHESA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10940278 IMPEL NEUROPHARMA Nozzles for nasal drug delivery Jan, 2033

(10 years from now)

US9919117 IMPEL NEUROPHARMA Nozzles for nasal drug delivery Mar, 2033

(10 years from now)

Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient

Treatment: Nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.725MG/SPRAY SPRAY, METERED;NASAL Prescription

106. Drug name - TURALIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9358235 DAIICHI SANKYO INC Kinase modulation, and indications therefor Jun, 2033

(10 years from now)

Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient

Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE CAPSULE;ORAL Prescription

107. Drug name - TYBOST

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718

(Pediatric)

GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent Apr, 2033

(10 years from now)

Drugs and Companies using COBICISTAT ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET;ORAL Prescription

108. Drug name - UKONIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9150579 TG THERAPS Selective PI3K delta inhibitors
Jul, 2033

(10 years from now)

US10570142 TG THERAPS Selective PI3K delta inhibitors
Jul, 2033

(10 years from now)

CN104470923B TG THERAPS Selective Pi3K Inhibitor
Jul, 2033

(10 years from now)

CN104470923A TG THERAPS Selective Pi3K Inhibitor
Jul, 2033

(10 years from now)

IN358166B TG THERAPS Selective Pi3K Delta Inhibitors
Jul, 2033

(10 years from now)

IN201500204P4 TG THERAPS Selective Pi3K Delta Inhibitors
Jul, 2033

(10 years from now)

EP3260455A1 TG THERAPS Selective Pi3K Delta Inhibitors
Jul, 2033

(10 years from now)

EP2870157B1 TG THERAPS Selective Pi3K Delta Inhibitors
Jul, 2033

(10 years from now)

EP3260455B1 TG THERAPS Selective Pi3K Delta Inhibitors
Jul, 2033

(10 years from now)

EP2870157A1 TG THERAPS Selective Pi3K Delta Inhibitors
Jul, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10072013 TG THERAPS Selective PI3K delta inhibitors Jul, 2033

(10 years from now)

US10981919 TG THERAPS Selective PI3K delta inhibitors Jul, 2033

(10 years from now)

US9669033 TG THERAPS Selective PI3K delta inhibitors Jul, 2033

(10 years from now)

Drugs and Companies using UMBRALISIB TOSYLATE ingredient

Treatment: Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen; relapsed or refractory follicular lymphoma (fl) who have received at least three prior lines of systemic therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

109. Drug name - ULTRAVATE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962028 SUN PHARM INDUSTRIES Topical steroid composition and method Jun, 2033

(10 years from now)

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Treatment: Use of a lotion containing halobetasol propionate for the treatment of corticosteroid-responsive dermatoses including psoriasis

Dosage: LOTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.05% LOTION;TOPICAL Prescription

110. Drug name - VASCEPA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9610272 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US11000499 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject Jun, 2033

(10 years from now)

US10894028 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease Jun, 2033

(10 years from now)

US10786478 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject Jun, 2033

(10 years from now)

US10792270 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease Jun, 2033

(10 years from now)

US10576054 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease Jun, 2033

(10 years from now)

US10668042 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject Jun, 2033

(10 years from now)

US10568861 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease Jun, 2033

(10 years from now)

US10555924 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease Jun, 2033

(10 years from now)

US10555925 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease Jun, 2033

(10 years from now)

US10383840 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease Jun, 2033

(10 years from now)

US10278936 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US10278937 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US10278935 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US9918954 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US9693986 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US9693985 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US9693984 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US9623001 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US9603826 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy Jun, 2033

(10 years from now)

US11116742 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject Jun, 2033

(10 years from now)

Drugs and Companies using ICOSAPENT ETHYL ingredient

Treatment: Use of vascepa as an adjunct to statin therapy to reduce the risk of cardiovascular death and/or unstable angina in an adult patient with elevated triglyceride levels (tg >= 150 mg/dl to about 500 mg/dl); Use of vascepa as an adjunct to statin therapy to reduce the risk of a second and further cardiovascular event in an adult patient with established cardiovascular disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of myocardial infarction in an adult patient with elevated triglyceride levels and established cv disease or diabetes mellitus and two or more additional risk factors for cv disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of a third and further cardiovascular event in an adult patient with elevated tg levels (>=150 mg/dl) and established cardiovascular disease; use of vascepa as an adjunct to statin therapy to reduce the risk of a second or further cardiovascular (cv) event in an adult patient with elevated tg levels (>= 150 mg/dl) and diabetes mellitus and 2 or more additional risk factors for cv disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of coronary revascularization in an adult patient with established cardiovascular disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of a major cardiovascular event in an adult patient with diabetes mellitus and two or more additional risk factors for cardiovascular disease; Use of vascepa with high intensity statin therapy to reduce the risk of a cv event in an adult patient with elevated triglyceride levels and (1) established cv disease, or (2) diabetes mellitus and two or more additional risk factors for cv disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of cardiovascular death in an adult patient with established cardiovascular disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of unstable angina in an adult patient with established cardiovascular disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of stroke in an adult patient with established cardiovascular disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of a cardiovascular event in an adult patient with elevated triglyceride levels and at least one risk factor for cardiovascular disease; Use of vascepa as an adjunct to statin therapy to reduce the risk of a cardiovascular event (cardiovascular death, coronary revascularization and/or unstable angina) in an adult patient with elevated triglyceride levels; Use of vascepa as an adjunct to statin therapy to reduce the risk of a cv event (cv death, coronary revascularization, unstable angina, stroke and/or myocardial infarction) in an adult patient with elevated triglyceride levels and diabetes mellitus; Use of vascepa as an adjunct to statin therapy to reduce the risk of coronary revascularization and/or unstable angina in an adult patient with elevated triglyceride levels (tg >= 150 mg/dl to about 500 mg/dl); Use of vascepa as an adjunct to statin therapy to reduce the risk of a cardiovascular event (coronary revascularization, unstable angina, stroke and/or myocardial infarction) in an adult patient with elevated triglyceride levels; Use of vascepa as an adjunct to statin therapy to reduce the risk of cardiovascular death and/or coronary revascularization in an adult patient with elevated triglyceride levels (tg >= 150 mg/dl to about 500 mg/dl); Use of vascepa as an adjunct to statin therapy to reduce the risk of cardiovascular death, coronary revascularization, and unstable angina in an adult patient with elevated triglyceride levels (tg >= 150 mg/dl to about 500 mg/dl); Use of vascepa as an adjunct to statin therapy to reduce the risk of a cardiovascular event in a patient with prior percutaneous coronary intervention

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
1GM CAPSULE;ORAL Prescription
500MG CAPSULE;ORAL Prescription

111. Drug name - VELTASSA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492476 VIFOR PHARMA Potassium-binding agents for treating hypertension and hyperkalemia Oct, 2033

(11 years from now)

US11123363 VIFOR PHARMA Potassium-binding agents for treating hypertension and hyperkalemia Oct, 2033

(11 years from now)

US9925212 VIFOR PHARMA Potassium-binding agents for treating hypertension and hyperkalemia Oct, 2033

(11 years from now)

Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient

Treatment: Treatment of hyperkalemia

Dosage: POWDER;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 8.4GM BASE/PACKET POWDER;ORAL Prescription
EQ 16.8GM BASE/PACKET POWDER;ORAL Prescription
EQ 25.2GM BASE/PACKET POWDER;ORAL Prescription

112. Drug name - VEMLIDY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate Feb, 2033

(10 years from now)

US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate Feb, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET;ORAL Prescription

113. Drug name - VENCLEXTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539251 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor Sep, 2033

(10 years from now)

US11110087 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor Sep, 2033

(10 years from now)

US10993942 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor Sep, 2033

(10 years from now)

Drugs and Companies using VENETOCLAX ingredient

Treatment: Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic leukemia (sll) in combination with a ga101 antibody such as obinutuzumab for one or more dosing periods, wherein the cll or sll is a cd20-expressing cancer; Treatment of acute myeloid leukemia (aml) by orally administering venetoclax with azacitidine or decitabine or low-dose cytarabine in adults 75 years or older or having certain comorbidities according to a dose ramp-up including a 100 mg per day dose; treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up including a 100 mg per day dose; Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up that includes a dose of 50 mg per day for 1 week followed by 100 mg per day for 1 week

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
50MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription

114. Drug name - VIBERZI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11160792 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations Mar, 2033

(10 years from now)

US10188632 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations Mar, 2033

(10 years from now)

US11007179 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations Mar, 2033

(10 years from now)

US11229627 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations Mar, 2033

(10 years from now)

US11090291 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations Mar, 2033

(10 years from now)

US9675587 ALLERGAN HOLDINGS Opioid receptor modulator dosage formulations Mar, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
75MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription

115. Drug name - VICTOZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265893

(Pediatric)

NOVO NORDISK INC Injection button Mar, 2033

(10 years from now)

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
18MG/3ML (6MG/ML) SOLUTION;SUBCUTANEOUS Prescription

116. Drug name - VIEKIRA PAK (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9629841 ABBVIE INC Formulations of pyrimidinedione derivative compounds Oct, 2033

(11 years from now)

US10201542 ABBVIE INC Formulations of pyrimidinedione derivative compounds Oct, 2033

(11 years from now)

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient

Treatment: Treatment of hcv infection using dasabuvir

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 250MG BASE;12.5MG, 75MG, 50MG TABLET;ORAL Discontinued

117. Drug name - VIVLODEX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9526734 ZYLA Formulation of meloxicam Mar, 2033

(10 years from now)

Drugs and Companies using MELOXICAM ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG CAPSULE;ORAL Discontinued
10MG CAPSULE;ORAL Discontinued

118. Drug name - VOSEVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8940718

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds May, 2033

(10 years from now)

US8921341

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds May, 2033

(10 years from now)

US8575135

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds May, 2033

(10 years from now)

More Information on Dosage
Strength Dosage Availability
400MG;100MG;100MG TABLET;ORAL Prescription

119. Drug name - VUMERITY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10080733 BIOGEN INC Prodrugs of fumarates and their use in treating various diseases
Sep, 2033

(10 years from now)

US8669281 BIOGEN INC Prodrugs of fumarates and their use in treating various diseases
Sep, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9090558 BIOGEN INC Prodrugs of fumarates and their use in treating various diseases Sep, 2033

(10 years from now)

Drugs and Companies using DIROXIMEL FUMARATE ingredient

Treatment: Method of treating multiple sclerosis

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
231MG CAPSULE, DELAYED RELEASE;ORAL Prescription

120. Drug name - VYLEESI (AUTOINJECTOR)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9700592 PALATIN TECHNOLOGIES Uses of bremelanotide in therapy for female sexual dysfunction Nov, 2033

(11 years from now)

US10286034 PALATIN TECHNOLOGIES Uses of bremelanotide in therapy for female sexual dysfunction Nov, 2033

(11 years from now)

US9352013 PALATIN TECHNOLOGIES Uses of bremelanotide in therapy for female sexual dysfunction Nov, 2033

(11 years from now)

Drugs and Companies using BREMELANOTIDE ACETATE ingredient

Treatment: Treatment of hypoactive sexual desire disorder (hsdd)

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML) SOLUTION;SUBCUTANEOUS Prescription

121. Drug name - WEGOVY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9764003 NOVO Use of long-acting GLP-1 peptides Jun, 2033

(10 years from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: Method for weight management according to a dose escalation schedule

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.25MG/0.5ML (0.25MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
0.5MG/0.5ML (0.5MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
1MG/0.5ML (1MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
1.7MG/0.75ML (1.7MG/0.75ML) SOLUTION;SUBCUTANEOUS Prescription
2.4MG/0.75ML (2.4MG/0.75ML) SOLUTION;SUBCUTANEOUS Prescription

122. Drug name - XATMEP

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10231927 AZURITY Methotrexate composition Jan, 2033

(10 years from now)

US11116724 AZURITY Methotrexate composition Jan, 2033

(10 years from now)

US9855215 AZURITY Methotrexate composition Jan, 2033

(10 years from now)

US9259427 AZURITY Methotrexate composition Jan, 2033

(10 years from now)

US10610485 AZURITY Methotrexate composition Jan, 2033

(10 years from now)

Drugs and Companies using METHOTREXATE SODIUM ingredient

Treatment: A method for treating acute lymphoblastic leukemia; treatment of juvenile rheumatoid arthritis; Treatment of juvenile rheumatoid arthritis; a method for treating acute lymphoblastic leukemia

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.5MG BASE/ML SOLUTION;ORAL Prescription

123. Drug name - XHANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033696 OPTINOSE US INC Nasal delivery devices May, 2033

(10 years from now)

US10179216 OPTINOSE US INC Nasal delivery devices Jul, 2033

(10 years from now)

US10478574 OPTINOSE US INC Nasal administration Nov, 2033

(11 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Treatment: Method of delivering fluticasone propionate to a nasal airway

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.093MG SPRAY, METERED;NASAL Prescription

124. Drug name - XIIDRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9085553 NOVARTIS LFA-1 inhibitor and methods of preparation and polymorph thereof Jul, 2033

(10 years from now)

US11058677 NOVARTIS LFA-1 inhibitor formulations Dec, 2033

(11 years from now)

Drugs and Companies using LIFITEGRAST ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
5% SOLUTION/DROPS;OPHTHALMIC Prescription

125. Drug name - XIPERE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636332 BAUSCH AND LOMB INC Methods and devices for the treatment of ocular diseases in human subjects Nov, 2033

(11 years from now)

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Treatment: Treatment of macular edema associated with uveitis

Dosage: SUSPENSION;INJECTION

More Information on Dosage
Strength Dosage Availability
40MG/ML SUSPENSION;INJECTION Prescription

126. Drug name - XTORO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9504691 MERLION PHARMS GMBH Finafloxacin suspension compositions Nov, 2033

(11 years from now)

Drugs and Companies using FINAFLOXACIN ingredient

Treatment: Treatment of acute otitis externa

Dosage: SUSPENSION/DROPS;OTIC

More Information on Dosage
Strength Dosage Availability
0.3% SUSPENSION/DROPS;OTIC Discontinued

127. Drug name - XYOSTED (AUTOINJECTOR)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10821072 ANTARES PHARMA INC Needle assisted jet injection administration of testosterone compositions Jun, 2033

(10 years from now)

Drugs and Companies using TESTOSTERONE ENANTHATE ingredient

Treatment: Method of administering testosterone enanthate subcutaneously

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
50MG/0.5ML (50MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
75MG/0.5ML (75MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription
100MG/0.5ML (100MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription

128. Drug name - XYREM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10213400 JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters Mar, 2033

(10 years from now)

US9486426 JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters Mar, 2033

(10 years from now)

US9050302 JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters Mar, 2033

(10 years from now)

US8772306 JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters Mar, 2033

(10 years from now)

US10864181 JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters Mar, 2033

(10 years from now)

US8772306

(Pediatric)

JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters Sep, 2033

(10 years from now)

US9486426

(Pediatric)

JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters Sep, 2033

(10 years from now)

US9050302

(Pediatric)

JAZZ PHARMS Method of administration of gamma hydroxybutyrate with monocarboxylate transporters Sep, 2033

(10 years from now)

Drugs and Companies using SODIUM OXYBATE ingredient

Treatment: Method of reducing adverse effects in patients suffering from excessive daytime sleepiness and/or cataplexy in narcolepsy who are concomitantly administered sodium oxybate and divalproex sodium; Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered.

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
0.5GM/ML SOLUTION;ORAL Prescription

129. Drug name - XYWAV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132107 JAZZ Gamma-hydroxybutyrate compositions and their use for the treatment of disorders Jan, 2033

(10 years from now)

US10195168 JAZZ Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders Jan, 2033

(10 years from now)

US8591922 JAZZ Gamma-hydroxybutyrate compositions and their use for the treatment of disorders Jan, 2033

(10 years from now)

US10675258 JAZZ Method of using gamma-hydroxybutyrate compositions for the treatment of disorders Jan, 2033

(10 years from now)

US8901173 JAZZ Gamma-hydroxybutyrate compositions and their use for the treatment of disorders Jan, 2033

(10 years from now)

US8772306 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters Mar, 2033

(10 years from now)

US9050302 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters Mar, 2033

(10 years from now)

US10213400 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters Mar, 2033

(10 years from now)

US9486426 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters Mar, 2033

(10 years from now)

US10864181 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters Mar, 2033

(10 years from now)

Drugs and Companies using CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE ingredient

Treatment: Treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy with a mixture of sodium, potassium, magnesium, and calcium salts of ghb; Method of treating patients with idiopathic hypersomnia with sodium oxybate when divalproex sodium is concomitantly administered; method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered.; Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered.; Method of reducing adverse effects in patients suffering from excessive daytime sleepiness and/or cataplexy in narcolepsy who are concomitantly administered sodium oxybate and divalproex sodium; Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with a salt of gamma-hydroxybutyrate when divalproex sodium is concomitantly administered

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
0.234GM/ML;0.096GM/ML;0.13GM/ML;0.04GM/ML SOLUTION;ORAL Prescription

130. Drug name - YOSPRALA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987231 GENUS LIFESCIENCES Compositions and methods for delivery of omeprazole plus acetylsalicylic acid Jan, 2033

(10 years from now)

US9539214 GENUS LIFESCIENCES Compositions and methods for delivery of omeprazole plus acetylsalicylic acid Mar, 2033

(10 years from now)

Drugs and Companies using ASPIRIN; OMEPRAZOLE ingredient

Treatment: For secondary prevention of cardiovascular and cerebrovascular events in patients at risk of developing aspirin-associated gastric ulcers; Treatment or secondary prevention of cardiovascular disease, cardiovascular events, or cerebrovascular events and risk-reduction of aspirin-associated gastric ulcers

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
81MG;40MG TABLET, DELAYED RELEASE;ORAL Discontinued
325MG;40MG TABLET, DELAYED RELEASE;ORAL Discontinued

131. Drug name - ZERVIATE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9254286

(Pediatric)

EYEVANCE Ophthalmic formulations of cetirizine and methods of use Jan, 2033

(10 years from now)

Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
EQ 0.24% BASE SOLUTION/DROPS;OPHTHALMIC Prescription

132. Drug name - ZOHYDRO ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10322120 RECRO GAINESVILLE Treating pain in patients with hepatic impairment Jul, 2033

(10 years from now)

US9326982 RECRO GAINESVILLE Treating pain in patients with hepatic impairment Jul, 2033

(10 years from now)

US9265760 RECRO GAINESVILLE Treating pain in patients with hepatic impairment Jul, 2033

(10 years from now)